{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021556","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.301532+00:00","generated_at":"2026-06-22T09:46:30.284317+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dyne Therapeutics Q3 net loss $41.4M; Phase 1/2 trials for DM1 and DMD underway with data H2 2023","bullets":["Net loss of $41.4M ($0.80 per share) vs $42.6M ($0.83) in Q3 2021; cash $248.1M funds operations through 2024.","R&D expense $34.7M, G&A $7.6M; R&D slightly down YoY.","ACHIEVE trial (DYNE-101 for DM1) and DELIVER trial (DYNE-251 for DMD) both enrolling; primary endpoints safety and tolerability.","DYNE-251 granted FDA Fast Track designation in October 2022.","Data from placebo-controlled portions of both trials anticipated in second half of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021556","json":"https://secwatch.observer/filing/0000950170-22-021556.json","markdown":"https://secwatch.observer/filing/0000950170-22-021556.md","text":"https://secwatch.observer/filing/0000950170-22-021556.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000095017022021556/0000950170-22-021556-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000095017022021556/dyn-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:46:30.284317+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ff3181596e9b53dd37f29c4389ee6cbba556db10","claim":"Dyne Therapeutics, Inc. reported the third quarter of 2022 results: net income Net loss for the quarter ended September 30, 2022 was $41.4 million, or $0.80 per basic and diluted share., EPS $0.80 per basic and diluted share.","evidence_excerpt":"Net loss for the quarter ended September 30, 2022 was $41.4 million, or $0.80 per basic and diluted share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017022021556/0000950170-22-021556-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2022"},{"label":"Net income","value":"Net loss for the quarter ended September 30, 2022 was $41.4 million, or $0.80 per basic and diluted share."},{"label":"EPS","value":"$0.80 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}